{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T10:53:24Z","timestamp":1781607204480,"version":"3.54.5"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Klinikum der Universit\u00e4t M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Recently, immune checkpoint inhibitors (ICIs) have driven profound changes in the treatment of non-small cell lung cancer (NSCLC). Their rapid integration into clinical routine is crucial for patient outcomes. However, prescribing patterns may not change immediately after authorization. Therefore, in this study we investigated factors associated with the adoption of ICI therapy for patients with advanced lung cancer in Germany following the initial regulatory approval.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this study we used German health insurance claims of 36,727 lung cancer patients diagnosed in 2015\u20132016. We included pre-treated patients with advanced disease. Factors potentially influencing the adoption of ICI therapies were analyzed, including demographics, residence type, hospital size, comorbidities, and metastasis location. Changes in prescribing patterns for ICI therapies were evaluated over three years using population-at-risk calculations with statistical analysis conducted using techniques including multivariate Cox regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Overall, we identified 9,726 pre-treated patients with advanced lung cancer in our dataset. Of these, 285 received ICI therapy during the course of the disease. These initial patients receiving ICI therapy were significantly younger and were more often treated in bigger hospitals. At first, uptake of ICI therapy was slow but started to increase from 1.1% in 01\/2017 to 8.6% in 12\/2019. Multivariate Cox regression showed that being treated in a bigger hospital (HR\u2009=\u20091.49,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001), having M1a vs. M1b or c metastases (HR\u2009=\u20092.65,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001), being diagnosed in 2016 vs. 2015 (HR\u2009=\u20093.39,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001), and having a comorbidity of COPD (HR\u2009=\u20091.46,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.004), led to higher, faster adoption of ICI therapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Introducing novel therapies necessitates a deliberate focus on disseminating information and enhancing accessibility across healthcare facilities of varying sizes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12889-025-23846-2","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T07:48:22Z","timestamp":1753861702000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Changes in prescribing patterns and access to immune checkpoint inhibitors in german lung cancer patients \u2013 a claims data analysis"],"prefix":"10.1186","volume":"25","author":[{"given":"Julia","family":"Walter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blerina","family":"Resuli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Sellmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Kauffmann-Guerrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toki","family":"Bolt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chukwuka","family":"Eze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Behr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Tufman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,30]]},"reference":[{"issue":"5","key":"23846_CR1","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1634\/theoncologist.2015-0507","volume":"21","author":"D Kazandjian","year":"2016","unstructured":"Kazandjian D, Suzman DL, Blumenthal G, Mushti S, He K, Libeg M, et al. FDA approval summary: nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy. Oncologist. 2016;21(5):634\u201342.","journal-title":"Oncologist"},{"issue":"10183","key":"23846_CR2","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","volume":"393","author":"TSK Mok","year":"2019","unstructured":"Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393(10183):1819\u201330.","journal-title":"Lancet"},{"issue":"22","key":"23846_CR3","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic Non-Small-Cell lung Cancer. N Engl J Med. 2018;378(22):2078\u201392.","journal-title":"N Engl J Med"},{"issue":"21","key":"23846_CR4","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","volume":"379","author":"L Paz-Ares","year":"2018","unstructured":"Paz-Ares L, Luft A, Vicente D, Tafreshi A, G\u00fcm\u00fc\u015f M, Mazi\u00e8res J, et al. Pembrolizumab plus chemotherapy for squamous Non-Small-Cell lung Cancer. N Engl J Med. 2018;379(21):2040\u201351.","journal-title":"N Engl J Med"},{"issue":"19","key":"23846_CR5","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, Hui R, Cs\u0151szi T, F\u00fcl\u00f6p A, et al. Pembrolizumab versus chemotherapy for PD-L1-Positive Non-Small-Cell lung Cancer. N Engl J Med. 2016;375(19):1823\u201333.","journal-title":"N Engl J Med"},{"issue":"7","key":"23846_CR6","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","volume":"20","author":"H West","year":"2019","unstructured":"West H, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(7):924\u201337.","journal-title":"Lancet Oncol"},{"issue":"14","key":"23846_CR7","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","volume":"383","author":"RS Herbst","year":"2020","unstructured":"Herbst RS, Giaccone G, de Marinis F, Reinmuth N, Vergnenegre A, Barrios CH, et al. Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC. N Engl J Med. 2020;383(14):1328\u201339.","journal-title":"N Engl J Med"},{"issue":"8","key":"23846_CR8","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.3390\/cancers12082313","volume":"12","author":"CA Uyl-de Groot","year":"2020","unstructured":"Uyl-de Groot CA, Heine R, Krol M, Verweij J. Unequal access to newly registered cancer drugs leads to potential loss of life-years in Europe. Cancers (Basel). 2020;12(8):2313.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"23846_CR9","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1186\/1472-6963-14-469","volume":"14","author":"\u00c1 Lubl\u00f3y","year":"2014","unstructured":"Lubl\u00f3y \u00c1. Factors affecting the uptake of new medicines: a systematic literature review. BMC Health Serv Res. 2014;14(1):469.","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"23846_CR10","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1186\/s40425-019-0771-1","volume":"7","author":"NJ Shah","year":"2019","unstructured":"Shah NJ, Al-Shbool G, Blackburn M, Cook M, Belouali A, Liu SV, et al. Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection. J Immunother Cancer. 2019;7(1):353.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"23846_CR11","doi-asserted-by":"publisher","first-page":"6637","DOI":"10.1038\/s41598-021-86081-w","volume":"11","author":"KB Vora","year":"2021","unstructured":"Vora KB, Ricciuti B, Awad MM. Exclusion of patients living with HIV from cancer immune checkpoint inhibitor trials. Sci Rep. 2021;11(1):6637.","journal-title":"Sci Rep"},{"issue":"2","key":"23846_CR12","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1159\/000503566","volume":"98","author":"J Galant-Swafford","year":"2019","unstructured":"Galant-Swafford J, Troesch A, Tran L, Weaver A, Doherty Taylor A, Patel Sandip P. Landscape of immune-related pneumonitis in cancer patients with asthma being treated with immune checkpoint blockade. Oncology. 2019;98(2):123\u201330.","journal-title":"Oncology"},{"issue":"1","key":"23846_CR13","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00262-019-02431-8","volume":"69","author":"R Shibaki","year":"2020","unstructured":"Shibaki R, Murakami S, Matsumoto Y, Yoshida T, Goto Y, Kanda S, et al. Association of immune-related pneumonitis with the presence of preexisting interstitial lung disease in patients with non-small lung cancer receiving anti-programmed cell death 1 antibody. Cancer Immunol Immunotherapy: CII. 2020;69(1):15\u201322.","journal-title":"Cancer Immunol Immunotherapy: CII"},{"issue":"1","key":"23846_CR14","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1186\/s12890-022-02190-w","volume":"22","author":"Z Zeng","year":"2022","unstructured":"Zeng Z, Qu J, Yao Y, Xu F, Lu S, Zhang P, et al. Clinical outcomes and risk factor of immune checkpoint inhibitors-related pneumonitis in non-small cell lung cancer patients with chronic obstructive pulmonary disease. BMC Pulm Med. 2022;22(1):458.","journal-title":"BMC Pulm Med"},{"issue":"5","key":"23846_CR15","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.21037\/tlcr-21-214","volume":"10","author":"J Zhou","year":"2021","unstructured":"Zhou J, Chao Y, Yao D, Ding N, Li J, Gao L, et al. Impact of chronic obstructive pulmonary disease on immune checkpoint inhibitor efficacy in advanced lung cancer and the potential prognostic factors. Translational Lung cancer Res. 2021;10(5):2148\u201362.","journal-title":"Translational Lung cancer Res"},{"key":"23846_CR16","unstructured":"AOK Bundesverband. Zahlen und Fakten 2015 [Available from: https:\/\/www.aok.de\/pk\/struktur-verwaltung\/wir-ueber-uns\/"},{"issue":"2","key":"23846_CR17","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1055\/s-0034-1396815","volume":"77","author":"E Swart","year":"2015","unstructured":"Swart E, Gothe H, Geyer S, Jaunzeme J, Maier B, Grobe TG, et al. [Good practice of secondary data analysis (GPS): guidelines and recommendations]. Gesundheitswesen. 2015;77(2):120\u20136.","journal-title":"Gesundheitswesen"},{"key":"23846_CR18","unstructured":"R Core Team. (2016). R: A language and environment for statistical computing. R Foundation for Statistical Computing. Vienna, Austria2016."},{"issue":"8","key":"23846_CR19","doi-asserted-by":"publisher","first-page":"e180798","DOI":"10.1001\/jamaoncol.2018.0798","volume":"4","author":"JM O\u2019Connor","year":"2018","unstructured":"O\u2019Connor JM, Fessele KL, Steiner J, Seidl-Rathkopf K, Carson KR, Nussbaum NC, et al. Speed of adoption of immune checkpoint inhibitors of programmed cell death 1 protein and comparison of patient ages in clinical practice vs pivotal clinical trials. JAMA Oncol. 2018;4(8):e180798.","journal-title":"JAMA Oncol"},{"issue":"12","key":"23846_CR20","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1001\/jamaoncol.2021.4971","volume":"7","author":"RB Parikh","year":"2021","unstructured":"Parikh RB, Min EJ, Wileyto EP, Riaz F, Gross CP, Cohen RB, et al. Uptake and survival outcomes following immune checkpoint inhibitor therapy among trial-ineligible patients with advanced solid cancers. JAMA Oncol. 2021;7(12):1843\u201350.","journal-title":"JAMA Oncol"},{"issue":"9","key":"23846_CR21","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1001\/jamaoncol.2019.2244","volume":"5","author":"TS Uldrick","year":"2019","unstructured":"Uldrick TS, Gon\u00e7alves PH, Abdul-Hay M, Claeys AJ, Emu B, Ernstoff MS, et al. Assessment of the safety of pembrolizumab in patients with HIV and advanced cancer-a phase 1 study. JAMA Oncol. 2019;5(9):1332\u20139.","journal-title":"JAMA Oncol"},{"issue":"7","key":"23846_CR22","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1001\/jamaoncol.2020.0465","volume":"6","author":"M Gonzalez-Cao","year":"2020","unstructured":"Gonzalez-Cao M, Mor\u00e1n T, Dalmau J, Garcia-Corbacho J, Bracht JWP, Bernabe R, et al. Assessment of the feasibility and safety of durvalumab for treatment of solid tumors in patients with HIV-1 infection: the phase 2 DURVAST study. JAMA Oncol. 2020;6(7):1063\u20137.","journal-title":"JAMA Oncol"},{"issue":"7","key":"23846_CR23","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1001\/jamaoncol.2018.6737","volume":"5","author":"MR Cook","year":"2019","unstructured":"Cook MR, Kim C. Safety and efficacy of immune checkpoint inhibitor therapy in patients with HIV infection and advanced-stage cancer: a systematic review. JAMA Oncol. 2019;5(7):1049\u201354.","journal-title":"JAMA Oncol"},{"issue":"3","key":"23846_CR24","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1093\/jnci\/djac203","volume":"115","author":"M Li","year":"2022","unstructured":"Li M, Liao K, Chen AJ, Cascone T, Shen Y, Lu Q, et al. Disparity in checkpoint inhibitor utilization among commercially insured adult patients with metastatic lung cancer. JNCI: J Natl Cancer Inst. 2022;115(3):295\u2013302.","journal-title":"JNCI: J Natl Cancer Inst"},{"issue":"3","key":"23846_CR25","first-page":"227","volume":"2","author":"E Lenci","year":"2021","unstructured":"Lenci E, Marcantognini G, Cognigni V, Lupi A, Rinaldi S, Cantini L, et al. Tumor burden as possible biomarker of outcome in advanced NSCLC patients treated with immunotherapy: a single center, retrospective, real-world analysis. Explor Target anti-tumor Therapy. 2021;2(3):227\u201339.","journal-title":"Explor Target anti-tumor Therapy"},{"issue":"19","key":"23846_CR26","doi-asserted-by":"publisher","first-page":"5737","DOI":"10.1158\/1078-0432.CCR-17-1434","volume":"23","author":"M Nishino","year":"2017","unstructured":"Nishino M, Dahlberg SE, Adeni AE, Lydon CA, Hatabu H, J\u00e4nne PA, et al. Tumor response dynamics of advanced Non-small cell lung Cancer patients treated with PD-1 inhibitors: imaging markers for treatment outcome. Clin cancer Research: Official J Am Association Cancer Res. 2017;23(19):5737\u201344.","journal-title":"Clin cancer Research: Official J Am Association Cancer Res"},{"issue":"15","key":"23846_CR27","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1001\/jama.2016.4059","volume":"315","author":"A Ribas","year":"2016","unstructured":"Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Kefford R, et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA. 2016;315(15):1600\u20139.","journal-title":"JAMA"},{"key":"23846_CR28","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.lungcan.2019.06.009","volume":"132","author":"DR Gandara","year":"2019","unstructured":"Gandara DR, Paul SM, Kowanetz M, Garon EB, Rizvi NA, et al. Phase III study of Atezolizumab as First-Line therapy in advanced NSCLC: Real-World uptake and outcomes in France. Lung Cancer. 2019;132:117\u201324. https:\/\/doi.org\/10.1016\/j.lungcan.2019.06.009.","journal-title":"Lung Cancer"},{"key":"23846_CR29","unstructured":"Royal College of Physicians. National Lung Cancer Audit Annual Report. 2019. London: RCP; 2020. https:\/\/www.rcplondon.ac.uk\/projects\/outputs\/national-lung-cancer-audit-annual-report-2019 (Accessed May 2025)."},{"key":"23846_CR30","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ejca.2021.04.00","volume":"146","author":"F Perrone","year":"2021","unstructured":"Perrone F, Riolo G, Di Maio M, Barni S, Donati C, et al. Real-world use of immune checkpoint inhibitors in advanced NSCLC: post-approval trends and outcomes in European cohorts. Eur J Cancer. 2021;146:123\u201333. https:\/\/doi.org\/10.1016\/j.ejca.2021.04.00.","journal-title":"Eur J Cancer"},{"issue":"6","key":"23846_CR31","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.jtho.2022.01.005","volume":"17","author":"D Fujimoto","year":"2022","unstructured":"Fujimoto D, Morimoto T, Kawazoe A, Saito R, Matsumoto K, et al. Clinical outcomes of immune checkpoint inhibitors in elderly and comorbid patients with advanced NSCLC: A European observational study. J Thorac Oncol. 2022;17(6):823\u201332. https:\/\/doi.org\/10.1016\/j.jtho.2022.01.005.","journal-title":"J Thorac Oncol"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-025-23846-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-025-23846-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-025-23846-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T10:05:32Z","timestamp":1781604332000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12889-025-23846-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,30]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["23846"],"URL":"https:\/\/doi.org\/10.1186\/s12889-025-23846-2","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,30]]},"assertion":[{"value":"23 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was carried out in accordance with Good Practice of Secondary Data Analysis guidelines. The ethics committee of the Ludwig-Alexander university Munich approved the conduction of this study without requiring informed consent due to the retrospective, anonymized nature of the dataset.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2588"}}